Upstream Bio, Inc. rose 10.8% on Monday, November 9, 2026, on 1,983,600 shares, 2.1 times its average daily volume. No headline about UPB came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
Upstream Bio, Inc. (UPB:NASDAQ) closed at $2.78 on November 13, 2026, down 2.80% on the day. The stock trades 91.7% below its 52-week high of $33.68 and 3.7% above its 52-week low of $2.68. Over the past year, it lost 89.2%. Upstream Bio, Inc. is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, UPB closed higher on 118 days (47%). Its best day was March 11, 2026 (+15.27%) and its worst was February 11, 2026 (-47.18%). The stock moved 10% or more in a single session 17 times.
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. We are developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin ("TSLP"), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Preclinical and clinical data to date demonstrate verekitug's highly potent inhibition of the TSLP receptor, which we believe will translate to a differentiated product profile, including improved clinical outcomes, substantially extended dosing intervals and the potential to treat a broad spectrum of patients.
Find more stocks like UPB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.